Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Bio-XL is a preclinical-stage drug development company developing new drug entities based on in-licensed technologies, from the early stage to the late-clinical and commercial stages.
The company is working toward an anticancer drug treatment based on the Klotho hormone, with a novel mechanism of action for triple-negative breast cancer and pancreatic cancer, as well as breast cancer prediction using digital pathology and artificial intelligence.
Bio-XL has a worldwide exclusive license for the commercialization of the technologies based on intellectual property from Sheba Medical Center in Israel and Cedars-Sinai Medical Center in the U.S.